{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470619424
| IUPAC_name = 3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1''H''-pyrazolo[4,3-''d'']pyrimidin-5-yl)-''N''-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
| image = Udenafil.svg
| width = 250

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = Not approved
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 93,9%
| metabolism = [[Liver]] (mainly [[CYP3A4]])
| elimination_half-life = 7.3–12.1 hours
| excretion = [[Bile|Biliary]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 268203-93-6
| ATC_prefix = G04
| ATC_suffix = BE11
| PubChem = 6918523
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06267
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5293720
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L5IB4XLY36
| KEGG = D10027
| KEGG_Ref = {{keggcite|changed|kegg}}

<!--Chemical data-->
| C=25 | H=36 | N=6 | O=4 | S=1 
| molecular_weight = 516.657 g/mol
| smiles = O=C2\N=C(/Nc1c(nn(c12)C)CCC)c3cc(ccc3OCCC)S(=O)(=O)NCCC4N(C)CCC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IYFNEFQTYQPVOC-UHFFFAOYSA-N
}}

The drug '''udenafil''', marketed under the trade name '''Zydena''', is within the [[PDE5 inhibitor|PDE<sub>5</sub> inhibitor]] class (which also includes [[avanafil]], [[sildenafil]], [[tadalafil]], and [[vardenafil]]).  Used, like other PDE<sub>5</sub> inhibitors, to treat [[erectile dysfunction]], udenafil was developed by Dong-A Pharmaceutical.<ref>[http://en.donga.co.kr/prd/prd01_view.jsp?mitgrp=FZYT Zydena (udenafil) product-information page.] Dong-A Pharmaceutical. Retrieved on April 13, 2009.</ref> With action of fairly rapid onset (peak [[blood plasma|plasma]] concentration after 1 to 1.5 hours) yet long duration (plasma [[half life]] of 11 to 13 hours), udenafil's [[pharmacokinetics]] allows once-daily dosage (in addition to on-demand use).<ref>{{cite journal| pmid=23554845 | doi=10.1177/1756287212470019 | pmc=3607490 | volume=5 | title=Udenafil: efficacy and tolerability in the management of erectile dysfunction | year=2013 | journal=Ther Adv Urol | pages=101–10 | last1 = Kang | first1 = SG | last2 = Kim | first2 = JJ}}</ref> Typical doses are 100 and 200&nbsp;mg. Udenafil is available in Korea, Russia, and the Philippines;<ref>[http://www.drugs.com/international/zydena.html "Zydena", ''Drugs.com'']</ref> in the United States, it has not been approved by the [[U.S. Food and Drug Administration]].

==References==
<references/>

{{Drugs for erectile dysfunction and PE}}
{{Phosphodiesterase inhibitors}}

[[Category:Lactams]]
[[Category:PDE5 inhibitors]]
[[Category:Phenol ethers]]
[[Category:Pyrazolopyrimidines]]
[[Category:Pyrrolidines]]
[[Category:Sulfonamides]]


{{genito-urinary-drug-stub}}